EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways

Ting Zhang, Chang Liu iD, Ning Zhong iD, Yichen Wang, Yiyun Huang, Xiaoqin Zhang iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910668 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ting Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Health Science Center, Ningbo University, Ningbo 315211, China. Hauptthemen laut MEDLINE: Schizophrenia, Receptors, N-Methyl-D-Aspartate, Cognitive Dysfunction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China, Young Doctor Innovation Research Program of Ningbo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cognitive impairment is a core feature of schizophrenia, playing a pivotal role in the pathogenesis and prognosis of this disorder. Cognitive impairment in schizophrenia encompasses a wide range of domains, including processing speed, episodic memory, working memory, and executive function. These deficits persist throughout the course of the illness and significantly impact functional outcomes and quality of life. Therefore, it is imperative to identify the biological basis of cognitive deficits in schizophrenia and develop effective treatments. The role of N-methyl-D-aspartate (NMDA) receptors in synaptic transmission and plasticity has long been recognized, making them potential targets for schizophrenia treatment. This review will focus on emerging pharmacology targeting NMDA receptors, offering strategies for the prevention and treatment of cognitive deficits in schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaReceptors, N-Methyl-D-AspartateCognitive DysfunctionHumansAnimalsAntipsychotic AgentsSignal TransductionNeuronal PlasticitySynaptic TransmissionMolecular Targeted Therapy

Stichwörter der Autor:innen

NMDA receptorcognitive impairmentexcitation/inhibition balanceschizophrenia

Substanzen

Receptors, N-Methyl-D-AspartateAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Pharmacology, Health Science Center, Ningbo University, Ningbo 315211, China.

ORCID-Profile: Chang Liu, Ning Zhong, Xiaoqin Zhang

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China
  • Young Doctor Innovation Research Program of Ningbo
  • Municipal Key R&D Program of Ningbo
  • 111 Project of China

Zitieren

APA

Zhang, T., Liu, C., Zhong, N., Wang, Y., Huang, Y., & Zhang, X. (2024). Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910668

Vancouver

Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X. Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910668

BibTeX
@article{Zhang2024,
  author = {Zhang, Ting and Liu, Chang and Zhong, Ning and Wang, Yichen and Huang, Yiyun and Zhang, Xiaoqin},
  title = {Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910668}
}
Kostenlos starten →